07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015 , a biosimilar of...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V. , Utrecht,...
01:19 , Sep 10, 2015 |  BC Extra  |  Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...